Alumis Inc. Common Stock
NASDAQ:ALMS · NASDAQ Global Select
+$0.21 today
Vol 1.77M · Avg 1.31M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
+736.07%
Period High
$29.98
Period Low
$2.80
Latest
$23.41
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$890.61M
Eton Pharmaceuticals, Inc.
NASDAQ:ETON
$873.15M
Omeros Corporation
NASDAQ:OMER
$722.67M
Ocugen, Inc.
NASDAQ:OCGN
$432.29M
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
$310.38M
Bicycle Therapeutics plc
NASDAQ:BCYC
$279.66M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$272.37M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$189.39M
ADC Therapeutics S.A.
NYSE:ADCT
$134.82M
What is the latest ALMS filing?
The latest filing shown is 4 dated May 27, 2026.
How many recent filings does ALMS have?
Intrinsic Alpha currently shows 20 recent filings for ALMS.
Explore More
Continue the stock analysis
Jump to another research area for this company.